News

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...
FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...
This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...